Catarina Guerreiro Simões

Catarina Guerreiro Simões

Auto-generated profile, based on publicly available information

Catarina Guerreiro Simões

Lysosomes and Disease Group, iNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2026 in BioChip Journal
Verified
Journal Article
Open access
PDF file
QRQuélia Ribeiro
Quélia Ribeiro
ELElizeth Lopes
Elizeth Lopes
IFInês S. Ferreira
Inês S. Ferreira
CSCatarina Guerreiro Simões
Catarina Guerreiro Simões
CVCarlos Miguel Vital
Carlos Miguel Vital
Otilia VieiraOtilia Vieira
Otilia Vieira
Despite pharmacological-, technological- and medical- advances, cardiovascular diseases (CVDs) remain the main cause of death and disability in the world. This underscores the urgent need to better understand the early stages of these diseases for effective prevention, as well as to develop patient-specific pharmacological approaches (personalized medicine) and novel therapies. Traditional in vitro and in vivo models often fail to accurately mimic human physiology, limiting their translational potential. In this context, microphysiological systems (MPS) have emerged as advanced in vitro platforms that integrate key physiological features of cardiovascular tissues. This review summarizes the state-of-the-art advancements in in vitro models for studying CVDs, with a particular focus on emerging 3D cardiac and vascular models. These models serve as essential tools for disease modelling, drug development, and toxicity testing. Key parameters to consider when developing cardiovascular MPS are highlighted, along with a discussion of the advantages and challenges associated with each model system. Graphical Abstract